The Latest Word on Reverse Payment Pharmaceutical Patent Settlements

The Latest Word on Reverse Payment Pharmaceutical Patent Settlements

Speaking Engagement
The April 2012 decision by the US Court of Appeals for the Eleventh Circuit in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (a.k.a. AndroGel), affirmed the dismissal of the FTC’s suit against so-called “reverse payment” settlements of pharmaceutical patent litigation, adopting the "scope of the patent" test. In July 2012, the US Court of Appeals for the Third Circuit rejected the scope of the patent test in favor of a presumption of illegality for reverse payment settlements in In Re: K-Dur Antitrust Litigation. This panel discussion, sponsored by the ABA Section of Antitrust Law's Health Care and Pharmaceuticals Committee, addresses these recent decisions and their implications. WilmerHale Partner Hartmut Schneider moderates this event.          

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.